Discovery and Biosynthesis of Gladiolin: A Burkholderia gladioli Antibiotic with Promising Activity against Mycobacterium tuberculosis.

@article{Song2017DiscoveryAB,
  title={Discovery and Biosynthesis of Gladiolin: A Burkholderia gladioli Antibiotic with Promising Activity against Mycobacterium tuberculosis.},
  author={Lijiang Song and Matthew Jenner and Joleen Masschelein and Cerith Jones and Matthew J Bull and Simon R. Harris and Ruben C. Hartkoorn and Anthony Vocat and Isolda Romero-Canel{\'o}n and Paul G. Coupland and Gordon Webster and Matthew H. Dunn and Rebecca Weiser and Christopher Paisey and Stewart T Cole and Julian Parkhill and Eshwar Mahenthiralingam and Gregory L Challis},
  journal={Journal of the American Chemical Society},
  year={2017},
  volume={139 23},
  pages={
          7974-7981
        }
}
An antimicrobial activity screen of Burkholderia gladioli BCC0238, a clinical isolate from a cystic fibrosis patient, led to the discovery of gladiolin, a novel macrolide antibiotic with potent activity against Mycobacterium tuberculosis H37Rv. Gladiolin is structurally related to etnangien, a highly unstable antibiotic from Sorangium cellulosum that is also active against Mycobacteria. Like etnangien, gladiolin was found to inhibit RNA polymerase, a validated drug target in M. tuberculosis… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-8 OF 8 CITATIONS

Burkholderia gladioli sinonasal infection.

  • European annals of otorhinolaryngology, head and neck diseases
  • 2019
VIEW 1 EXCERPT
CITES BACKGROUND

Not all Pseudomonas aeruginosa are equal: strains from industrial sources possess uniquely large multireplicon genomes

Rebecca Weiser, Angharad E Green, +10 authors Eshwar Mahenthiralingam
  • Microbial genomics
  • 2019
VIEW 1 EXCERPT
CITES METHODS